{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:53:17Z","timestamp":1770781997243,"version":"3.50.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00059-017-4605-y","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T05:25:28Z","timestamp":1503465928000},"page":"518-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease","Wirkungen von Paricalcitol auf kardiovaskul\u00e4re Ergebnisse und Nierenfunktion bei Patienten mit chronischer Nierenerkrankung"],"prefix":"10.1007","volume":"43","author":[{"given":"X.","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"4605_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2174\/157016109788340686","volume":"7","author":"I Gouni-Berthold","year":"2009","unstructured":"Gouni-Berthold I, Krone W, Berthold HK (2009) Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 7:414\u2013422","journal-title":"Curr Vasc Pharmacol"},{"key":"4605_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.ajkd.2011.12.035","volume":"60","author":"SU Nigwekar","year":"2012","unstructured":"Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139\u2013156","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1053\/j.ajkd.2012.04.014","volume":"60","author":"J Kendrick","year":"2012","unstructured":"Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M (2012) Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 60:567\u2013575","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pbiomolbio.2006.02.004","volume":"92","author":"AR Webb","year":"2006","unstructured":"Webb AR (2006) Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92:17\u201325","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"4605_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.maturitas.2009.12.013","volume":"65","author":"J Parker","year":"2010","unstructured":"Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH (2010) Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 65:225\u2013236","journal-title":"Maturitas"},{"key":"4605_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2369-14-199","volume":"14","author":"Z Zheng","year":"2013","unstructured":"Zheng Z, Shi H, Jia J, Li D, Lin S (2013) Vitamin D supplementation and mortality risk in chronic kidney disease: a\u00a0meta-analysis of 20 observational studies. BMC Nephrol 14:199","journal-title":"BMC Nephrol"},{"key":"4605_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"MF Holick","year":"2007","unstructured":"Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266\u2013281","journal-title":"N. Engl. J. Med."},{"key":"4605_CR8","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","volume":"10","author":"JL Finch","year":"1999","unstructured":"Finch JL, Brown AJ, Slatopolsky E (1999) Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J\u00a0Am Soc Nephrol 10:980\u2013985","journal-title":"J Am Soc Nephrol"},{"key":"4605_CR9","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1053\/ajkd.1998.v32.pm9808142","volume":"32","author":"E Slatopolsky","year":"1998","unstructured":"Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a\u00a0new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32:S40\u2013S47","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J\u00a0Am Soc Nephrol 15:2208\u20132218","journal-title":"J Am Soc Nephrol"},{"key":"4605_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2215\/CJN.03000311","volume":"7","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang W, Zhang X, Li X, Chen J (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a\u00a0meta-analysis. Clin J Am Soc Nephrol 7:391\u2013400","journal-title":"Clin J Am Soc Nephrol"},{"key":"4605_CR12","first-page":"320560","volume":"2013","author":"T Han","year":"2013","unstructured":"Han T, Rong G, Quan D, Shu Y, Liang Z, She N, Liu M, Yang B, Cheng G, Lv Y, Stern L (2013) Meta-analysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int 2013:320560","journal-title":"Biomed Res Int"},{"key":"4605_CR13","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823\u20132828","journal-title":"Kidney Int."},{"key":"4605_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/HYPERTENSIONAHA.108.113159","volume":"52","author":"P Alborzi","year":"2008","unstructured":"Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R (2008) Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a\u00a0randomized double-blind pilot trial. Hypertension 52:249\u2013255","journal-title":"Hypertension"},{"key":"4605_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/ki.2012.311","volume":"83","author":"IH Boer De","year":"2013","unstructured":"De Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J (2013) Paricalcitol does not improve glucose metabolism in patients with stage 3\u20134 chronic kidney disease. Kidney Int 83:323\u2013330","journal-title":"Kidney Int."},{"key":"4605_CR17","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","volume":"376","author":"D Zeeuw De","year":"2010","unstructured":"De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a\u00a0randomised controlled trial. Lancet 376:1543\u20131551","journal-title":"Lancet"},{"issue":"4","key":"4605_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","volume":"54","author":"S Fishbane","year":"2009","unstructured":"Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a\u00a0randomized trial. Am J Kidney Dis 54(4):647\u2013652. doi: 10.1053\/j.ajkd.2009.04.036","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/dme.12606","volume":"32","author":"C Joergensen","year":"2015","unstructured":"Joergensen C, Tarnow L, Goetze JP, Rossing P (2015) Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a\u00a0randomized trial. Diabet Med 32:374\u2013381","journal-title":"Diabet Med"},{"key":"4605_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-163","author":"T Larsen","year":"2013","unstructured":"Larsen T, Mose FH, Bech JN, Pedersen EB (2013) Effect of paricalcitol on renin and albuminuria in non-diabetic stage III\u2013IV chronic kidney disease: A randomized placebo-controlled trial. BMC Nephrol. doi: 10.1186\/1471-2369-14-163","journal-title":"BMC Nephrol"},{"issue":"6","key":"4605_CR21","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","volume":"164","author":"H Tamez","year":"2012","unstructured":"Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, Thadhani R (2012) Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 164(6):902\u2013909.e2. doi: 10.1016\/j.ahj.2012.09.018","journal-title":"Am. Heart J."},{"issue":"7","key":"4605_CR22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307(7):674\u2013684. doi: 10.1001\/jama.2012.120","journal-title":"JAMA"},{"key":"4605_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jdiacomp.2015.01.004","volume":"29","author":"TK Thethi","year":"2015","unstructured":"Thethi TK, Bajwa MA, Ghanim H, Jo C, Weir M, Goldfine AB, Umpierrez G, Desouza C, Dandona P, Fang-Hollingsworth Y, Raghavan V, Fonseca VA (2015) Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease. J Diabetes Complicat 29:433\u2013437","journal-title":"J. Diabetes Complicat."},{"key":"4605_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","volume":"25","author":"AYM Wang","year":"2014","unstructured":"Wang AYM, Fang F, Chan J, Wen YY, Qing S, Chan IHS, Lo G, Lai KN, Lo WK, Lam CWK, Yu CM (2014) Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial. J\u00a0Am Soc Nephrol 25:175\u2013186","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4605_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/hypertensionaha.114.03748","volume":"64","author":"C Zoccali","year":"2014","unstructured":"Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F (2014) Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 64(5):1005\u20131011. doi: 10.1161\/hypertensionaha.114.03748","journal-title":"Hypertension"},{"issue":"6","key":"4605_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ajt.12227","volume":"13","author":"H Amer","year":"2013","unstructured":"Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, Heilman RL, Mazur MJ, Hamawi K, Larson TS, Kumar R (2013) Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant 13(6):1576\u20131585. doi: 10.1111\/ajt.12227","journal-title":"Am J Transplant"},{"key":"4605_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","volume":"49","author":"LA Greenbaum","year":"2007","unstructured":"Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49:814\u2013823","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR28","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","volume":"32","author":"F Llach","year":"1998","unstructured":"Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E (1998) Suppression of parathyroid hormone secretion in hemodialysis patients by a\u00a0novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 32:S48\u2013S54","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000441364","volume":"42","author":"K Lundwall","year":"2015","unstructured":"Lundwall K, Jorneskog G, Jacobson SH, Spaak J (2015) Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial. Am J Nephrol 42:265\u2013273","journal-title":"Am. J. Nephrol."},{"key":"4605_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/ajkd.2001.27697","volume":"38","author":"SM Moe","year":"2001","unstructured":"Moe SM, Zekonis M, Harezlak J, Ambrosius WT, Gassensmith CM, Murphy CL, Russell RR, Batiuk TD (2001) A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 38:792\u2013802","journal-title":"Am. J. Kidney Dis."},{"key":"4605_CR31","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1016\/j.transproceed.2010.07.077","volume":"42","author":"V Perez","year":"2010","unstructured":"Perez V, Sanchez A, Bayes B, Navarro-Munoz M, Lauzurica R, Pastor MC, Romero R (2010) Effect of paricalcitol on the urinary peptidome of kidney transplant patients. Transplant Proc 42:2924\u20132927","journal-title":"Transplant Proc"},{"key":"4605_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000109398","volume":"28","author":"EA Ross","year":"2008","unstructured":"Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM (2008) Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Am J Nephrol 28:97\u2013106","journal-title":"Am. J. Nephrol."},{"key":"4605_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.2013111185","volume":"26","author":"M Trillini","year":"2015","unstructured":"Trillini M, Cortinovis M, Ruggenenti P, Loaeza JR, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N (2015) Paricalcitol for secondary hyperparathyroidism in renal transplantation. J\u00a0Am Soc Nephrol 26:1205\u20131214","journal-title":"J Am Soc Nephrol"},{"key":"4605_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI0215219","volume":"110","author":"YC Li","year":"2002","unstructured":"Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a\u00a0negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229\u2013238","journal-title":"J. Clin. Invest."},{"key":"4605_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","volume":"39","author":"MC Corretti","year":"2002","unstructured":"Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a\u00a0report of the International Brachial Artery Reactivity Task Force. J\u00a0Am Coll Cardiol 39:257\u2013265","journal-title":"J Am Coll Cardiol"},{"key":"4605_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/ajh.2010.199","volume":"24","author":"JM Geleijnse","year":"2011","unstructured":"Geleijnse JM (2011) Vitamin D and the prevention of hypertension and cardiovascular diseases: a\u00a0review of the current evidence. Am J Hypertens 24:253\u2013262","journal-title":"Am J Hypertens"},{"key":"4605_CR37","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","volume":"27","author":"S Laurent","year":"2006","unstructured":"Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27:2588\u20132605","journal-title":"Eur. Heart J."},{"issue":"10","key":"4605_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/nep.12505","volume":"20","author":"XH Li","year":"2015","unstructured":"Li XH, Feng L, Yang ZH, Liao YH (2015) The effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis. Nephrology (Carlton) 20(10):706\u2013714. doi: 10.1111\/nep.12505","journal-title":"Nephrology (Carlton)"},{"key":"4605_CR39","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/ajh.2009.88","volume":"22","author":"KJ Schmitz","year":"2009","unstructured":"Schmitz KJ, Skinner HG, Bautista LE, Fingerlin TE, Langefeld CD, Hicks PJ, Haffner SM, Bryer-Ash M, Wagenknecht LE, Bowden DW, Norris JM, Engelman CD (2009) Association of 25-hydroxyvitamin D with blood pressure in predominantly 25-hydroxyvitamin D deficient Hispanic and African Americans. Am J Hypertens 22:867\u2013870","journal-title":"Am J Hypertens"},{"key":"4605_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10654-013-9874-z","volume":"29","author":"SK Kunutsor","year":"2014","unstructured":"Kunutsor SK, Burgess S, Munroe PB, Khan H (2014) Vitamin D and high blood pressure: causal association or epiphenomenon? Eur J Epidemiol 29:1\u201314","journal-title":"Eur J Epidemiol"},{"key":"4605_CR41","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jacc.2008.08.050","volume":"52","author":"JH Lee","year":"2008","unstructured":"Lee JH, O\u2019keefe JH, Bell D, Hensrud DD, Holick MF (2008) Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J\u00a0Am Coll Cardiol 52:1949\u20131956","journal-title":"J Am Coll Cardiol"},{"key":"4605_CR42","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/ajcn\/80.6.1666","volume":"80","author":"BJ Boucher","year":"2004","unstructured":"Boucher BJ, John WG, Noonan K (2004) Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 80:1666 (author reply 1666\u20131667)","journal-title":"Am. J. Clin. Nutr."},{"key":"4605_CR43","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1464-5491.2007.02360.x","volume":"25","author":"JA Sugden","year":"2008","unstructured":"Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD (2008) Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320\u2013325","journal-title":"Diabet Med"},{"key":"4605_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jsbmb.2006.12.098","volume":"103","author":"RU Simpson","year":"2007","unstructured":"Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J\u00a0Steroid Biochem Mol Biol 103:521\u2013524","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"4605_CR45","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/ki.2008.408","volume":"74","author":"M Freundlich","year":"2008","unstructured":"Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394\u20131402","journal-title":"Kidney Int."},{"key":"4605_CR46","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1681\/ASN.2006050520","volume":"17","author":"X Tan","year":"2006","unstructured":"Tan X, Li Y, Liu Y (2006) Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J\u00a0Am Soc Nephrol 17:3382\u20133393","journal-title":"J Am Soc Nephrol"},{"key":"4605_CR47","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1681\/ASN.2007060666","volume":"19","author":"X Tan","year":"2008","unstructured":"Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J\u00a0Am Soc Nephrol 19:1741\u20131752","journal-title":"J Am Soc Nephrol"},{"key":"4605_CR48","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1681\/ASN.2013030203","volume":"24","author":"MH Borst De","year":"2013","unstructured":"De Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ (2013) Active vitamin D treatment for reduction of residual proteinuria: a\u00a0systematic review. J\u00a0Am Soc Nephrol 24:1863\u20131871","journal-title":"J Am Soc Nephrol"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4605-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T16:52:39Z","timestamp":1659372759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4605-y"}},"subtitle":["A meta-analysis","Eine Metaanalyse"],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4605"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4605-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]},"assertion":[{"value":"3 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"X.\u00a0Hu, J.\u00a0Shang, W.\u00a0Yuan, S.\u00a0Zhang, Y.\u00a0Jiang, B.\u00a0Zhao, Y.\u00a0Duan, J.\u00a0Xiao, and Z.\u00a0Zhao declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}